Freedom of Information Act 2000 – Request Reference FoI/23/575
Leukaemia Treatment

Information Requested:

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
   - Azacitidine monotherapy
   - Low dose cytarabine (LoDAC) monotherapy
   - Venetoclax + azacitidine
   - Venetoclax + LoDAC
   - Ivosidenib
   - Intensive chemotherapy-based regimen
   - Other

Answer:

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
   - Azacitidine monotherapy
   - Low dose cytarabine (LoDAC) monotherapy
   - Venetoclax + azacitidine
   - Venetoclax + LoDAC
   - Ivosidenib
   - Intensive chemotherapy-based regimen
   - Other

Note: this should only include patients who have started first-line treatment during the 6-month window

Answer:

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

Answer:

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

Answer:

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

Answer:

Response Details:

In response to questions 1—5:

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the Fees Regulations for this amount of work (18 hours) is £450 for the UHB. The Fees Regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

In accordance with our duty to advise and assist under section 16 of the Act, the UHB can confirm that the majority of myeloid prescriptions remain in paper form.